Resmed (RMD) EBITDA (2009 - 2026)

Resmed's EBITDA history runs 18 years deep, the most recent figure standing at $499.8 million for Q1 2026.

• Quarterly EBITDA rose 17.25% year-over-year to $499.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 17.4% YoY) and the FY2025 annual result came in at $1.7 billion, up 27.69% from the prior year.
• EBITDA was $499.8 million for Q1 2026 at Resmed, up from $491.7 million in the prior quarter.
• Across five years, EBITDA topped out at $499.8 million in Q1 2026 and bottomed at $234.3 million in Q1 2022.
• A 5-year average of $356.8 million and a median of $374.6 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA retreated 1.82% — and 2024, when it jumped 51.67%.
• Resmed's EBITDA stood at $280.2 million in 2022, then declined by 1.82% to $275.1 million in 2023, then soared by 51.67% to $417.2 million in 2024, then climbed by 17.84% to $491.7 million in 2025, then advanced by 1.66% to $499.8 million in 2026.
• Business Quant data shows RMD's EBITDA at $499.8 million in Q1 2026, $491.7 million in Q4 2025, and $446.5 million in Q3 2025.